Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131511) titled 'A controlled study on the treatment of adult idiopathic membranous nephropathy with rituximab combined with glucocorticoids and cyclophosphamide' on Sept. 3.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Yiwu Central Hospital CN
Condition:
idiopathic membranous nephropathy
Intervention:
Rituximab Group:Rituximab 375 mg/m2 on day 1 and day 15. Observe treatment response
repeat administration after 6 months if necessary.
Cyclophosphamide Group:Prednisone 1 mg/kg/d + Cyclophosphamide 15 mg/kg.
Prednisone (or equivalent dose of other corticosteroids) is used at full dose for 8 weeks...